2018 IPO

electroCore Stock

electroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders.

Sign up today and learn more about electroCore Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About electroCore Stock

electroCore LLC is a U.S.-based neuroscience and bioelectronic medicine healthcare technology company dedicated to improving patient outcomes through technological advancement. The company is focused on developing its proprietary non-invasive Vagus Nerve Stimulation (nVNS) therapies for the treatment of multiple conditions in neuropsychology, metabolic disorders and immunology. The company’s initial target is the treatment of primary headache, specifically migraine and cluster headache, and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society.

Funding History

November 2012$500K
June 2014$55.0M
August 2016$1.5M
September 2017$36.0M
November 2017$34.0M


Chief Medical Officer

Peter S. Staats, MD

Chief Executive Officer

Francis Amato

Global Vice President, Sales and Marketing

Dan Duhart

Vice President, Quality Assurance

Mike Romaniw

Co-Founder, Chief Science & Strategy Officer

J. P. Errico

Vice President, Scientific, Medical and Governmental Affairs

Eric Liebler

Co-Founder and Chief Technical Officer

Steve Mendez

Chief Financial Officer

Glenn S. Vraniak

Vice President, Research

Bruce J. Simon, PhD


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: